Global Asthma Therapeutics Market By Drug (Anti-Inflammatory Drugs, Bronchodilators, Combination Therapy), By Product (Dry Powder Inhalers, Metered Dose Inhalers, Mist Inhalers, Nebulizer), By Route (Inhalation, Oral, Parenteral) - Growth, Future Prospects And Competitive Analysis, 2016 - 2024

Asthma is the chronic respiratory disease which mainly affects the airways of the lung, characterized by wheezing, coughing, breathlessness, and chest tightness. Asthma can be caused by genetic or environmental factors. There is no cure for asthma but it can be controlled by using different medications. Unknown etiology of the disease is a major challenge to the asthma therapeutic market.

The report titled “Global Asthma Therapeutics Market- Growth, Future Prospects and Competitive Analysis, 2016–2024” offers strategic insights into the overall asthma therapeutics market along with the market size and estimates for the duration 2016 to 2024. The research study covers in-depth analysis of market segments based on drug class, product type, route of administration and different geographical region.

In order to help strategic decision makers, the report also includes competitive profiling of the leading players in global asthma therapeutic market, attractive investment proposition and market positioning of key manufacturers sections. Other in-depth analysis provided in the report includes:

Geographically, the global asthma therapeutic market is studied for the following regional markets:

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • Rest of Asia Pacific
• Latin America
• Middle East and Africa
•  

Market size and forecast for these regional and country level markets are presented in this study for the period 2014-2024. Market growth rates for the forecast period 2016-2024 are also included in this report, considering 2015 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global asthma therapeutics market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global asthma therapeutics market. This report concludes with company profiles section that highlights major information about the key players engaged in global asthma therapeutics market. In-depth competitive environment analysis and historical years (2014) market size data are also provided in the report. 

Thus, the research study provides a holistic view of the global asthma therapeutics market, offering market size and estimates for the period from 2016 to 2024, keeping in mind the above-mentioned factors.

Based on the route of administration, the global asthma therapeutics market is segmented as follows:  

• Inhalation
• Oral
• Parenteral
•  

In the base year 2015, inhaled drugs segment was the largest revenue generating segment in global asthma therapeutic market, due to advantages associated with use of inhalation drug therapy such as rapid onset of action, less systemic toxicity and higher concentration availability at the site of action. Bronchodilators, corticosteroids are usually given by inhalation route. Matered dose inhaler, dry powder inhaler and nebulizer are generally used to deliver inhalation drug in asthma. 

Use of inhaled corticosteroids in combination therapy is a therapeutic trend observed in the market. The rise in the incidence of asthma, increasing compliance for the inhalation asthma therapeutics provide opportunities for manufacturers to invest in the inhaler device market. GlaxoSmithKline's Advair, Boehringer Ingelheim's Spiriva, AstraZeneca’s Symbicort are the major contributors in inhaled asthma drug market. However patent expiry of some blockbusters drugs such as Symbicort and Flovent leads to reduce the overall revenue in global inhalation drug market.

Theophylline, corticosteroids in combination with short-acting beta agonists and Leukotriene modifiers are generally given by oral route to treat asthma. Oral blockbuster drug Singulair manufactured by Merck is currently suffering sales losses due to generic counterparts available in the market. Corticosteroids, aminophyllines, β2-agonist are generally given by parenteral route. Intravenous drug therapy is recommended when inhaled therapy cannot be used, such as in emergency conditions. Novartis’s blockbuster drug Xolair is given by subcutaneous route and it is the only biologic therapy licensed in many countries for the treatment of asthma.

For the purpose of this study, the Asthma Therapeutics market is categorized into:

• North America
• Europe
• Asia Pacific
• Latin America (LATAM)
• Middle East and Africa (MEA)

Asthma is a chronic lung disease of the airways that causes recurring episodes of wheezing, breathlessness, chest tightness and coughing. For the treatment of asthma bronchodilators and anti-inflammatory drugs are generally prescribe depending on the disease condition.

In base year 2015, North America was largest contributor in global asthma therapeutics market and occupied a significant portion of the global market. Higher prices of asthma medications and the lack of generic asthma inhalers drives the US asthma market. 

North America market will grow faster during forecast period due to increasing pollution coupled with a rise prevalence of asthma, expected launch of pipeline molecules and a delay in the surge of generic competition in this market. Also high cost of treatment and increasing demand of asthma therapeutics contribute the market growth in this region. Europe is the second largest market in terms of revenue for asthma therapeutics and it is anticipated to grow steady rate during forecast period. The prevalence of asthma increased in the latter part of the 20th century, but now prevalence is stable in many European countries. 

The market in the Europe is dominated by the UK, Germany, France, Italy, and Spain. In some countries such as Finland and France, the active participation of government health departments for asthma control would further drive the market in this regions. Key factor such as economic development, increasing healthcare awareness, high growth rate, rising funding by government agencies and private organizations in Asia Pacific region expected to drive the market growth throughout the forecast period 2016-2024. China, Japan, South Korea, India, and Australia dominate the global asthma market in the Asia Pacific region.